Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

New combinations and targeted therapies for acute myeloid leukemia on the horizon

The treatment landscape for acute myeloid leukemia (AML) is evolving rapidly, as research discoveries at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and other academic cancer centers advance new, more effective therapies for this aggressive blood cancer.

11 Dec 2023

CAR-T cell therapy remains viable for patients in lymphoma remission, study finds

A study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins.

11 Dec 2023

New drug combo shows promise in targeting RAS-mutant multiple myeloma

The combination of a drug and a protein fragment prevents the growth of blood cancer cells, a new study in mice shows.

11 Dec 2023

Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS

A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into the underlying mechanisms of gene mutations commonly seen in patients with myelodysplastic syndromes (MDS) and other myeloid neoplasms.

11 Dec 2023

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.

11 Dec 2023

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD Anderson Cancer Center.

11 Dec 2023

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

11 Dec 2023

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.

11 Dec 2023

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine's Abramson Cancer Center.

11 Dec 2023

MD Anderson and Rigel partner to expand olutasidenib evaluation in AML and other cancers

The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development collaboration to expand the evaluation of olutasidenib in acute myeloid leukemia (AML) and other hematologic cancers.

8 Dec 2023

New drug combo fights breast cancer with brain metastases

A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival among patients with unresectable locally advanced or metastatic HER2-positive breast cancer, compared with T-DM1 alone, according to results from the HER2CLIMB-02 trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.

6 Dec 2023

Investigating IDO1 and PDL1: Key immune checkpoints in cutaneous leishmaniasis research

In this Interview News Med talks to Dr. Nidhi Dey about immune checkpoints IDO1 and PDL1 and how they relate to cutaneous leishmaniasis research.

From TissueGnostics 5 Dec 2023

FDA clears Beckman Coulter Life Sciences AQUIOS STEM System for stem cell analysis

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, has received 510(k) clearance from the Food and Drug Administration (FDA) to distribute its popular AQUIOS STEM System in the United States.

From Beckman Coulter Life Sciences 4 Dec 2023

RNA-based therapy shows promise for treating leukemia in animal models

Each year, about 13,000 people in Deutschland are diagnosed with leukemia, an umbrella term that encompasses various forms of blood cancer.

27 Nov 2023

Genetic vulnerability of leukemia cells uncovered

Leukemia is the most common type of cancer in children. Treatment involves intensive chemotherapy, which has severe side effects due to its non-specific mode of action.

22 Nov 2023

AI tools show promise in personalized cancer treatment, but lag behind human experts

Treating cancer is becoming increasingly complex, but also offers more and more possibilities. After all, the better a tumor's biology and genetic features are understood, the more treatment approaches there are.

20 Nov 2023

Falk Trust awards $1.35 million to Case Western Reserve researchers for cancer and diabetic retinopathy treatments

A combined $1.35 million from the Dr. Ralph and Marian Falk Medical Research Trust was awarded to two researchers from the Case Western Reserve University School of Medicine to advance their work on finding more effective treatments-;and better options-;for two debilitating diseases.

17 Nov 2023

Researchers discover genetic mechanism behind pancreatic cancer metastasis

Pancreatic cancer is tricky to manage because it spreads easily and early, and the tumors have a unique biological makeup.

15 Nov 2023

Stand Up To Cancer unveils new gastroesophageal cancer research teams and awards

Stand Up To Cancer (SU2C) today announced three Research Teams focused on bringing new therapies to clinical trials for the treatment of gastroesophageal cancer (GEC).

15 Nov 2023

Clinical trial underway for novel human milk-based microbiome therapy

In a breakthrough for human milk science, researchers at City of Hope, Los Angeles, have dosed the first patient in a Phase 2a clinical trial evaluating a novel therapy for blood cancer patients undergoing allogeneic hematopoietic stem cell transplantation.

10 Nov 2023

Hematology News and Research

Further Reading

New combinations and targeted therapies for acute myeloid leukemia on the horizon

CAR-T cell therapy remains viable for patients in lymphoma remission, study finds

New drug combo shows promise in targeting RAS-mutant multiple myeloma

Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

MD Anderson and Rigel partner to expand olutasidenib evaluation in AML and other cancers

New drug combo fights breast cancer with brain metastases

Investigating IDO1 and PDL1: Key immune checkpoints in cutaneous leishmaniasis research

FDA clears Beckman Coulter Life Sciences AQUIOS STEM System for stem cell analysis

RNA-based therapy shows promise for treating leukemia in animal models

Genetic vulnerability of leukemia cells uncovered

AI tools show promise in personalized cancer treatment, but lag behind human experts

Falk Trust awards $1.35 million to Case Western Reserve researchers for cancer and diabetic retinopathy treatments

Researchers discover genetic mechanism behind pancreatic cancer metastasis

Stand Up To Cancer unveils new gastroesophageal cancer research teams and awards

Clinical trial underway for novel human milk-based microbiome therapy

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News